Our railways are an important part of our national transportation network. Our railways are an important part of our national...... Read more.

ITHACA, NY -- The Reimagining Public Safety Collaborative of the City of Ithaca and Tompkins County, N.Y., published a draft report in response to New York State Executive Order 203... Read more.

With all that’s happened over the last year, the smoke and devastation of last year’s wildfires may seem like a distant memory for some of us. Indeed, our typical February... Read more.

Ipswich District Crime Prevention would like to remind all road users to take their time and drive safely on Queensland roads. Already, we are faced with... Read more.

With the warmer temperatures and the sun out comes more bikers on Wichita streets and highways. With that comes a reminder to take extra caution, especially in the aftermath of a a winter storm.... Read more.

Celyn Eadon is regarded as one of the most dangerous and violent prisoners in the State... Read more.

The panel has also voiced their view against the umpire's call that has been influencing the LBW decisions... Read more.

A fan account of the Master Blaster took to Twitter to upload a video where Sachin Tendulkar can be seen sweating it out in indoor nets.... Read more.

Safety for the employees and inmates at the Montana State Prison (MSP) is one of Warden Jim Salmonsen’s top priorities. So, when 2020 brought some much-needed technology updates to MSP,... Read more.

Tag, you're it. Will Broncos tag safety Justin Simmons in back-to-back years?... Read more.

Along with his 30 years' experience in law enforcement working through the ranks as patrol officer, patrol supervisor, chief of detectives, and chief of police.... Read more.

TCEQ's Executive Director Toby Baker said they were focused on reaching out to water systems operators to help connect them with testing labs as quickly as possible.... Read more.

Syndio leaving Pioneer Square due to employee safety concerns - Puget Sound Business Journal - Puget Sound Business Journal (Seattle)... Read more.

Safety and efficacy of an rAd26 and rAd5 vector - based heterologous prime - boost COVID - 19 vaccine: An interim analysis of a randomized controlled phase 3 trial in Russia... Read more.

Snowstorms across the U.S. delayed the delivery of vaccine doses last week. While vaccination efforts are proceeding as cases decline across the United States, we�re not out of the woods yet. In the meantime, here are the answers to some pandemic-related questions you may have.... Read more.

Efficacy and safety of a supplement combination on hand pain among people with symptomatic hand osteoarthritis an internet - based, randomised clinical trial the RADIANT study... Read more.

WATCH: Sachin Tendulkar Back at Nets Ahead of Road Safety World Series | Master Blaster | Sachin Tendulkar Records | Cricket News | SRT Batting Video... Read more.

Traffic flow in part of Temuka�s main street will be reduced to one lane for safety work around the town clock.... Read more.

The newly renovated Inn at Water's Edge in Ludlow reopened for business in March 2020 — just in time for the COVID-19 pandemic to close...... Read more.

TEL AVIV, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. The committee found no safety issues with the trial and recommended its continuation as planned. "This review continues the trend of encouraging reviews that have taken place since the clinical trial began," said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics. "The trial continues to enroll on track in the US, Europe and Israel. We look forward to the next DSMC review during the third quarter of 2021, followed by completion of enrollment at the end of 2021 or in early 2022.” In March 2020, the Company announced results of the first interim analysis in the OVAL study, which reviewed unblinded data and assessed CA-125 response, measured according to the GCIG criteria, in the first 60 enrolled subjects evaluable for CA-125 analysis. The overall response rate across both arms was 53%. The response rate in the treatment arm (VB-111 in addition to weekly paclitaxel) was at least 10% higher than in the control, i.e., 58% or higher. In patients who had post-dosing fever, which is a marker for VB-111 treatment, the response rate was 69%. According to the Company update on November 16, 2020, a high response rate of >50% in the total evaluable patient population was maintained with approximately 200 patients enrolled. About the OVAL study (NCT03398655)OVAL is an international Phase 3 randomized pivotal registration enabling clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum-resistant ovarian cancer. The study is planned to enroll 400 patients. OVAL is conducted in collaboration with the GOG Foundation, Inc., an independent international non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. About VB-111 (ofranergene obadenovec)VB-111 is an investigational first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is a unique biologic agent that uses a dual mechanism to target solid tumors. Its mechanism combines blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. VB-111 has received an Orphan Designation for the treatment of ovarian cancer from the European Commission. VB-111 has also received orphan drug designation in both the US and Europe, and fast track designation in the US for prolongation of survival in patients with rGBM. VB-111 successfully demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer. About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. For additional information visit: www.vblrx.com. Forward Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. In particular, the DSMC recommendation that the OVAL trial proceed is not assurance that the trial will meet its primary endpoint of overall survival once completed, or that we will obtain positive results to support further development of this candidate. A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. CONTACT:Burns McClellan for VBL TherapeuticsLee Roth (investors) / Ryo Imai (media)[email protected] / [email protected]+1-212-213-0006... Read more.

Music department adjusts to new safety protocols a year into pandemic - The Collegian - The Collegian... Read more.